Breast cancer and combined oral contraceptives: An Italian case-control study

Carlo La Vecchia; Fabio Parazzini; Eva Negri; Peter Boyle; Antonella Gentile; Adriano Decarli; Silvia Franceschi

doi:10.1016/0277-5379(89)90306-4

Breast cancer and combined oral contraceptives: An Italian case-control study

Carlo La Vecchia, Fabio Parazzini, Eva Negri, Peter Boyle, Antonella Gentile, Adriano Decarli, Silvia Franceschi

Research output: Contribution to journal › Article

Abstract

The risk of breast cancer in relation to use of oral contraceptives was evaluated using data from a hospital-based case-control study from Northern Italy on 1517 cases below age 60 and 1351 controls admitted for acute diseases unrelated to any of the known or potential risk factors for breast cancer. The multivariate relative risk for ever vs. never users was 1.3 (95% confidence interval = 1.0-1.7). However, the risk was not related to duration of use: indeed the highest risk was observed among short-term users (

Original language	English
Pages (from-to)	1613-1618
Number of pages	6
Journal	European Journal of Cancer and Clinical Oncology
Volume	25
Issue number	11
DOIs	https://doi.org/10.1016/0277-5379(89)90306-4
Publication status	Published - 1989

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/0277-5379(89)90306-4

Fingerprint Dive into the research topics of 'Breast cancer and combined oral contraceptives: An Italian case-control study'. Together they form a unique fingerprint.

Cite this

La Vecchia, C., Parazzini, F., Negri, E., Boyle, P., Gentile, A., Decarli, A., & Franceschi, S. (1989). Breast cancer and combined oral contraceptives: An Italian case-control study. European Journal of Cancer and Clinical Oncology, 25(11), 1613-1618. https://doi.org/10.1016/0277-5379(89)90306-4

@article{650403b329204ba19539ab959cfd7140,

title = "Breast cancer and combined oral contraceptives: An Italian case-control study",

abstract = "The risk of breast cancer in relation to use of oral contraceptives was evaluated using data from a hospital-based case-control study from Northern Italy on 1517 cases below age 60 and 1351 controls admitted for acute diseases unrelated to any of the known or potential risk factors for breast cancer. The multivariate relative risk for ever vs. never users was 1.3 (95% confidence interval = 1.0-1.7). However, the risk was not related to duration of use: indeed the highest risk was observed among short-term users (",

author = "{La Vecchia}, Carlo and Fabio Parazzini and Eva Negri and Peter Boyle and Antonella Gentile and Adriano Decarli and Silvia Franceschi",

year = "1989",

doi = "10.1016/0277-5379(89)90306-4",

language = "English",

volume = "25",

pages = "1613--1618",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - Breast cancer and combined oral contraceptives

T2 - An Italian case-control study

AU - La Vecchia, Carlo

AU - Parazzini, Fabio

AU - Negri, Eva

AU - Boyle, Peter

AU - Gentile, Antonella

AU - Decarli, Adriano

AU - Franceschi, Silvia

PY - 1989

Y1 - 1989

N2 - The risk of breast cancer in relation to use of oral contraceptives was evaluated using data from a hospital-based case-control study from Northern Italy on 1517 cases below age 60 and 1351 controls admitted for acute diseases unrelated to any of the known or potential risk factors for breast cancer. The multivariate relative risk for ever vs. never users was 1.3 (95% confidence interval = 1.0-1.7). However, the risk was not related to duration of use: indeed the highest risk was observed among short-term users (

AB - The risk of breast cancer in relation to use of oral contraceptives was evaluated using data from a hospital-based case-control study from Northern Italy on 1517 cases below age 60 and 1351 controls admitted for acute diseases unrelated to any of the known or potential risk factors for breast cancer. The multivariate relative risk for ever vs. never users was 1.3 (95% confidence interval = 1.0-1.7). However, the risk was not related to duration of use: indeed the highest risk was observed among short-term users (

UR - http://www.scopus.com/inward/record.url?scp=0024369139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024369139&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(89)90306-4

DO - 10.1016/0277-5379(89)90306-4

M3 - Article

C2 - 2591454

AN - SCOPUS:0024369139

VL - 25

SP - 1613

EP - 1618

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -